Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of E7130 in Subjects With Solid Tumors
jRCT2080223823Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2018
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of E7130 in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC) and transitional cell carcinoma (TCC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Safety and tolerability of E7130 and Recommended dose for expansion. Started Feb 2018; status: completed.
02
Drugs
E7130
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2080223823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223823.